Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced the expiration, as of 11:59 p.m., New York City time, on May 26, 2015, of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of its outstanding debt securities.

 

Approximately $534.4 million in aggregate principal amount of the notes subject to the tender offer were validly tendered and not validly withdrawn on or prior to 5 p.m., New York City time, on May 11, 2015, the early tender date for the tender offer, which amount exceeds the tender cap. Bristol-Myers Squibb accepted for purchase the aggregate principal amount of the notes listed in the table below and purchased such notes on May 13, 2015. Holders of notes subject to the tender offer who validly tendered and did not validly withdraw their notes on or prior to the early tender date received the total consideration for notes accepted for purchase by Bristol-Myers Squibb, which included an early tender premium of $30 per $1,000 principal amount of notes tendered by such holders and accepted for purchase by Bristol-Myers Squibb.

Since holders of notes subject to the tender offer validly tendered and did not validly withdraw an aggregate principal amount of notes in excess of the tender cap on or prior to the early tender date, Bristol-Myers Squibb did not accept for purchase any additional tenders of notes made after the early settlement date. The tender offer was conducted upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 28, 2015, and the related Letter of Transmittal, as amended by Bristol-Myers Squibb’s press release on May 12, 2015.

Goldman, Sachs & Co. and Morgan Stanley & Co. LLC served as dealer managers for the tender offer, and D.F. King & Co., Inc. served as tender agent and information agent for the tender offer.

This press release is not a tender offer to purchase or a solicitation of acceptance of a tender offer, which was made only pursuant to the terms of the Offer to Purchase, as amended by Bristol-Myers Squibb’s press release on May 12, 2015. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer was deemed made on behalf of Bristol-Myers Squibb by Goldman, Sachs & Co. or Morgan Stanley & Co. LLC, or one or more registered brokers or dealers under the laws of such jurisdiction.

About Bristol-Myers Squibb :
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:
Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Laura Hortas, 609-252-4587
laura.hortas@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com

Advertisement - Oliver